Plain-English translation of NCT07052253 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether or —new immunotherapy drugs—work better when combined with a daily tablet called TT-00420 to treat advanced hepatocellular carcinoma (liver cancer). The study will enroll about 100 patients and compare these combination treatments to see which is most effective and safe. Some patients will receive only the daily tablet to help researchers understand how much benefit comes from adding the immunotherapy drugs.
Advanced liver cancer that has spread or cannot be removed by surgery is very difficult to treat, and current options have limited effectiveness. This medication combination targets cancer cells in new ways and may help patients live longer and maintain better quality of life.
You likely qualify if…
You likely don't qualify if…
You will take a daily tablet at home and receive intravenous infusions of the immunotherapy medication once every three weeks at a clinic or hospital. The study has two phases: first, a small safety phase with 3–6 patients per treatment group to make sure the combination is safe, followed by a larger phase with 20–30 patients per group. You will have regular blood tests, imaging scans, and clinic visits to check how well the treatment is working and to monitor for side effects.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Akeso
Collaborators
TransThera Sciences (Nanjing), Inc.
Enrollment target
~100 participants
Started
July 2025
Primary completion
May 2027
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ting Liu, M.D.
Akeso
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.